Nascobal nasal spray (cyanocobalamin, USP) + Vitamin B12-ratiopharm N, injection solution
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Focus: Bioavailability
Conditions
Focus: Bioavailability
Trial Timeline
Feb 1, 2011 → May 1, 2011
NCT ID
NCT01306123About Nascobal nasal spray (cyanocobalamin, USP) + Vitamin B12-ratiopharm N, injection solution
Nascobal nasal spray (cyanocobalamin, USP) + Vitamin B12-ratiopharm N, injection solution is a phase 1 stage product being developed by Swedish Orphan Biovitrum for Focus: Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT01306123. Target conditions include Focus: Bioavailability.
What happened to similar drugs?
0 of 1 similar drugs in Focus: Bioavailability were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01306123 | Phase 1 | Completed |
Competing Products
2 competing products in Focus: Bioavailability
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| S303 Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells (RBCs) | Cerus | Phase 2 | 25 |
| S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - Control | Cerus | Phase 3 | 30 |